| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | TOP1MT |
| Uniprot No | Q969P6 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 51-601aa |
| 氨基酸序列 | VKWRQLEHKG PYFAPPYEPL PDGVRFFYEG RPVRLSVAAE EVATFYGRML DHEYTTKEVF RKNFFNDWRK EMAVEEREVI KSLDKCDFTE IHRYFVDKAA ARKVLSREEK QKLKEEAEKL QQEFGYCILD GHQEKIGNFK IEPPGLFRGR GDHPKMGMLK RRITPEDVVI NCSRDSKIPE PPAGHQWKEV RSDNTVTWLA AWTESVQNSI KYIMLNPCSK LKGETAWQKF ETARRLRGFV DEIRSQYRAD WKSREMKTRQ RAVALYFIDK LALRAGNEKE DGEAADTVGC CSLRVEHVQL HPEADGCQHV VEFDFLGKDC IRYYNRVPVE KPVYKNLQLF MENKDPRDDL FDRLTTTSLN KHLQELMDGL TAKVFRTYNA SITLQEQLRA LTRAEDSIAA KILSYNRANR VVAILCNHQR ATPSTFEKSM QNLQTKIQAK KEQVAEARAE LRRARAEHKA QGDGKSRSVL EKKRRLLEKL QEQLAQLSVQ ATDKEENKQV ALGTSKLNYL DPRISIAWCK RFRVPVEKIY SKTQRERFAW ALAMAGEDFE F |
| 预测分子量 | 69,8 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下为示例格式的TOP1MT重组蛋白相关参考文献(非真实文献，供参考)：
1. **《Mitochondrial TOP1MT重组蛋白在结直肠癌中的表达及化疗增敏机制研究》**
作者：Zhang L, et al.
摘要：研究通过原核系统表达人源TOP1MT重组蛋白，证实其在结直肠癌细胞线粒体DNA损伤修复中的关键作用，并发现其过表达可增强奥沙利铂的化疗敏感性。
2. **《重组TOP1MT蛋白的酶学特性及对氧化应激的调控》**
作者：Wang Y, et al.
摘要：利用哺乳动物细胞表达体系纯化TOP1MT重组蛋白，发现其具有特异性DNA解旋酶活性，并通过减少线粒体ROS缓解氧化应激导致的细胞凋亡。
3. **《TOP1MT基因敲除模型与重组蛋白功能互补实验》**
作者：Johnson R, et al.
摘要：构建TOP1MT敲除小鼠模型，通过体外重组蛋白回补实验证明该蛋白对维持心肌细胞线粒体基因组稳定性至关重要。
4. **《基于冷冻电镜的TOP1MT重组蛋白结构解析》**
作者：Chen H, et al.
摘要：首次报道TOP1MT重组蛋白的高分辨率三维结构，揭示其催化中心与ATP结合域的关键氨基酸残基，为靶向药物设计提供结构基础。
(注：以上为模拟文献，建议通过PubMed/Google Scholar以“TOP1MT recombinant protein”为关键词检索真实文献。)
TOP1MT (mitochondrial topoisomerase I) is a nuclear-encoded enzyme localized exclusively in mitochondria, where it regulates mitochondrial DNA (mtDNA) topology by resolving replication and transcription-induced supercoils. Unlike its nuclear counterpart (TOP1), TOP1MT exhibits distinct biochemical properties, including resistance to camptothecin, a classic TOP1 inhibitor. This enzyme plays a critical role in maintaining mtDNA integrity and facilitating mitochondrial genome replication, particularly under oxidative stress or during rapid energy demand.
The recombinant TOP1MT protein is engineered to study its structure-function relationships and therapeutic potential. Produced via heterologous expression systems (e.g., E. coli or mammalian cells), it retains enzymatic activity to cleave and religate DNA strands through a conserved tyrosine residue (Tyr-394 in humans). Structural studies reveal a unique N-terminal mitochondrial targeting sequence and a core domain homologous to bacterial topoisomerases, reflecting evolutionary conservation of DNA maintenance mechanisms.
Research on recombinant TOP1MT has gained momentum due to its implications in mitochondrial disorders, cancer, and aging. Its overexpression has been linked to impaired mitochondrial function and increased reactive oxygen species production, while deficiencies correlate with mtDNA depletion syndromes. Recently, TOP1MT has emerged as a potential target for cancer therapy, as mitochondrial genome instability contributes to tumor progression and chemoresistance. Investigations also explore its role in metabolic diseases and neurodegenerative conditions associated with mitochondrial dysfunction. Current efforts focus on developing selective inhibitors/modulators to exploit TOP1MT's unique properties while avoiding nuclear TOP1-related toxicity.
×
